# Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

> **NCT05322473** · PHASE2 · COMPLETED · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 234 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Sonelokimab (M1095)
- **DRUG:** Adalimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05322473
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-25
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-08-30
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322473, "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05322473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*